Drug Development

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

As CEO Gareth Sheridan takes the stage, his company's abuse-deterrent tech, AVERSA™, promises a new front in the opioid crisis. But can it deliver?

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

A new partnership is bringing advanced, U.S.-based manufacturing to a rare cancer drug, aiming to solve daily patient challenges and bolster national supply chains.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.